Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives
Ioanna A. Anastasiou, Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos, Irene Karampela, Maria Dalamaga · 2025
Read Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives by Ioanna A. Anastasiou, Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos, Irene Karampela, Maria Dalamaga (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785648.txt.
Description
Ioanna Anastasiou and co-authors review in this 2025 paper a blood condition called CHIP, short for clonal hematopoiesis of indeterminate potential. In CHIP, a blood stem cell with a mutation grows into a large clone, yet no blood cancer is present. The state is common with age and shows in more than a fifth of people over eighty.
The review links CHIP to heart and metabolic disease, not just cancer risk. Carriers face notably higher rates of heart events and death, and mouse work ties some mutations to vessel swelling and clots. The authors weigh screening limits and new drug ideas, and frame CHIP as a risk factor that care may one day treat.
Catalog record
| CREATOR | Ioanna A. Anastasiou, Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos, Irene Karampela, Maria Dalamaga |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 80 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |